<DOC>
	<DOC>NCT00623558</DOC>
	<brief_summary>The aim of the study is to investigate the efficacy and safety of cetuximab, docetaxel, cisplatin combination as induction therapy in locally advanced head and neck squamous cell carcinoma.</brief_summary>
	<brief_title>Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Unresectable, locally advanced (cT4b &amp;/or cN23) HNSCC ECOG performance status 01 Age 18 or older than 18 years Measurable disease by RECIST criteria Having signed informed consent ALT and AST&lt;2.5 times ULN Serum albumin level ≥3.0g/dL Serum AKP &lt; 2.5 times ULN Bilirubin level &lt; 1.5mg/dL Serum creatinine &lt;1.5 times ULN WBC&gt;3000/mm3, absolute neutrophil count ≥1500/mm3, platelet&gt;75,000/mm3, Hb&gt;9g/dl Previous cytotoxic chemotherapy for HNSCC Radiotherapy for targeted lesions within six months Previous EGFR pathwaytargeting therapy Prior surgery for cancer (excluding diagnostic biopsy within 4 weeks prior to study entry) Distant metastatic disease Heart failure, coronary artery disease, myocardial infarction within the last 6 months Known allergy to any study treatment Pregnancy or lactation period Any investigational agent within the past 28 days Other previous malignancy within 5 year, except adequately treated in situ cervical cancer, or nonmelanoma skin cancer Legal incapacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>head and neck neoplasm</keyword>
	<keyword>cetuximab</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
	<keyword>radiotherapy</keyword>
</DOC>